News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,085 Results
Type
Article (46124)
Company Profile (334)
Press Release (660627)
Section
Business (208944)
Career Advice (2169)
Deals (35958)
Drug Delivery (103)
Drug Development (82091)
Employer Resources (187)
FDA (16266)
Job Trends (15195)
News (351963)
Policy (33146)
Tag
Academia (2719)
Alliances (50614)
Alzheimer's disease (1265)
Approvals (16186)
Artificial intelligence (139)
Bankruptcy (357)
Best Places to Work (11718)
Biotechnology (230)
Breast cancer (119)
Cancer (1055)
Cardiovascular disease (89)
Career advice (1817)
Cell therapy (236)
Clinical research (64839)
Collaboration (379)
Compensation (189)
COVID-19 (2608)
C-suite (91)
Data (1047)
Diabetes (152)
Diagnostics (6283)
Earnings (85645)
Employer resources (161)
Events (112822)
Executive appointments (284)
FDA (16776)
Funding (338)
Gene therapy (182)
GLP-1 (619)
Government (4474)
Healthcare (19041)
Infectious disease (2693)
Inflammatory bowel disease (109)
Interviews (341)
IPO (16492)
Job creations (3835)
Job search strategy (1564)
Layoffs (433)
Legal (8009)
Lung cancer (172)
Manufacturing (179)
Medical device (13323)
Medtech (13328)
Mergers & acquisitions (19521)
Metabolic disorders (413)
Neuroscience (1535)
NextGen Class of 2024 (6702)
Non-profit (4632)
Northern California (1425)
Obesity (244)
Opinion (196)
Patents (101)
People (58173)
Phase I (20131)
Phase II (28544)
Phase III (21295)
Pipeline (443)
Postmarket research (2633)
Preclinical (8794)
Radiopharmaceuticals (240)
Rare diseases (211)
Real estate (6208)
Regulatory (21933)
Research institute (2463)
Resumes & cover letters (374)
Southern California (1271)
Startups (3762)
United States (13266)
Vaccines (574)
Weight loss (184)
Date
Last 7 days (924)
Last 30 days (3461)
Last 365 days (36156)
2024 (32780)
2023 (40858)
2022 (51924)
2021 (56501)
2020 (54903)
2019 (47648)
2018 (35937)
2017 (33085)
2016 (32665)
2015 (38767)
2014 (32375)
2013 (27536)
2012 (29798)
2011 (30535)
2010 (29032)
Location
Africa (788)
Arizona (199)
Asia (38758)
Australia (6364)
California (3226)
Canada (1256)
China (241)
Colorado (147)
Connecticut (144)
Europe (84047)
Florida (439)
Georgia (120)
Illinois (352)
Indiana (197)
Kansas (98)
Maryland (580)
Massachusetts (2563)
Michigan (166)
Minnesota (283)
New Jersey (937)
New York (940)
North Carolina (722)
Northern California (1425)
Ohio (134)
Pennsylvania (822)
South America (1166)
Southern California (1271)
Texas (442)
Utah (90)
Washington State (356)
707,085 Results for "dermavant sciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Biotech Beach
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Dermavant Sciences has received approval in Japan for tapinarof cream, 1% for the treatment of both adults with psoriasis and patients 12 years of age and older with atopic dermatitis.
June 25, 2024
·
5 min read
Press Releases
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
·
11 min read
Business
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
·
16 min read
Press Releases
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
September 18, 2024
·
16 min read
Biotech Beach
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
April 29, 2024
·
5 min read
Drug Development
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
Dermavant Sciences today announced that the data from ADORING 1 and ADORING 2, two identical, double-blind, randomized, vehicle-controlled pivotal Phase 3 trials of VTAMA® (tapinarof) cream, 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology.
May 21, 2024
·
8 min read
Drug Development
Dermavant to Present New ADORING Data Including Treatment of Patients with Skin of Color from Phase 3 Trials of VTAMA® (tapinarof) Cream, 1% in Adults and Children 2 Years of Age and Older with Atopic Dermatitis at the 2024 AAD Annual Meeting
Dermavant Sciences announced that new ADORING data including treatment of patients with skin of color from Phase 3 trials of VTAMA® cream, 1% in adults and children 2 years of age and older with atopic dermatitis will be presented at the 2024 American Academy of Dermatology Annual Meeting, to be held from March 8-12 in San Diego, California.
March 1, 2024
·
6 min read
News
Dermavant Presents Data on Achievement of No-to-Minimal Itch and Sleep Improvement in Atopic Dermatitis Patients as Young as Two Years Old at American College of Allergy, Asthma and Immunology Annual Meeting
October 24, 2024
·
6 min read
Business
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.
October 13, 2023
·
6 min read
1 of 70,709
Next
